TY - JOUR
T1 - Proximity interactome analysis of Lassa polymerase reveals eRF3a/GSPT1 as a druggable target for host-directed antivirals
AU - Fang, Jingru
AU - Pietzsch, Colette
AU - Witwit, Haydar
AU - Tsaprailis, George
AU - Crynen, Gogce
AU - Frank Cho, Kelvin
AU - Ting, Alice Y.
AU - Bukreyev, Alexander
AU - Saphire, Erica Ollmann
AU - De la Torre, Juan Carlos
N1 - Funding Information:
ACKNOWLEDGMENTS. We thank Beatrice Cubitt from the de la Torre Lab (Scripps Research, CA) for helping with the cloning of pCI-FLAG-GSPT1 plasmid and preparation of LASV MG plasmid stocks. We thank Sharon Schendel at La Jolla Institute for Immunology (LJI) for manuscript editing, Zbigniew Mikulski of the Microscopy Core Facility (LJI) for microscopy training, and NIH S10OD021831 for sponsoring the Zeiss laser-scanning microscopy (LSM) 880 microscope. We thank Paul Schimmel (Scripps Research, CA) for providing us with anti-RARS and anti-AIMP2 antibodies and Tianying Zhang (Scripps Research, CA) for the mouse monoclonal antibody to LCMV GP2. This research was supported by institutional funds of LJI (E.O.S.) and NIH/NIAID grants AI125626 and AI128556 (J.C.d.l.T.). J.F. was supported by the Donald E. and Delia B. Baxter Foundation Fellowship. This is publication # 30107 from Scripps Research.
Publisher Copyright:
© 2022 National Academy of Sciences. All rights reserved.
PY - 2022/7/26
Y1 - 2022/7/26
N2 - Completion of the Lassa virus (LASV) life cycle critically depends on the activities of the virally encoded, RNA-dependent RNA polymerase in replication and transcription of the viral RNA genome in the cytoplasm of infected cells. The contribution of cellular proteins to these processes remains unclear. Here, we applied proximity proteomics to define the interactome of LASV polymerase in cells under conditions that recreate LASV RNA synthesis. We engineered a LASV polymerase-biotin ligase (TurboID) fusion protein that retained polymerase activity and successfully biotinylated the proximal proteome, which allowed the identification of 42 high-confidence LASV polymerase interactors. We subsequently performed a small interfering RNA (siRNA) screen to identify those interactors that have functional roles in authentic LASV infection. As proof of principle, we characterized eukaryotic peptide chain release factor subunit 3a (eRF3a/GSPT1), which we found to be a proviral factor that physically associates with LASV polymerase. Targeted degradation of GSPT1 by a small-molecule drug candidate, CC-90009, resulted in strong inhibition of LASV infection in cultured cells. Our work demonstrates the feasibility of using proximity proteomics to illuminate and characterize yet-to-be-defined host-pathogen interactome, which can reveal new biology and uncover novel targets for the development of antivirals against highly pathogenic RNA viruses.
AB - Completion of the Lassa virus (LASV) life cycle critically depends on the activities of the virally encoded, RNA-dependent RNA polymerase in replication and transcription of the viral RNA genome in the cytoplasm of infected cells. The contribution of cellular proteins to these processes remains unclear. Here, we applied proximity proteomics to define the interactome of LASV polymerase in cells under conditions that recreate LASV RNA synthesis. We engineered a LASV polymerase-biotin ligase (TurboID) fusion protein that retained polymerase activity and successfully biotinylated the proximal proteome, which allowed the identification of 42 high-confidence LASV polymerase interactors. We subsequently performed a small interfering RNA (siRNA) screen to identify those interactors that have functional roles in authentic LASV infection. As proof of principle, we characterized eukaryotic peptide chain release factor subunit 3a (eRF3a/GSPT1), which we found to be a proviral factor that physically associates with LASV polymerase. Targeted degradation of GSPT1 by a small-molecule drug candidate, CC-90009, resulted in strong inhibition of LASV infection in cultured cells. Our work demonstrates the feasibility of using proximity proteomics to illuminate and characterize yet-to-be-defined host-pathogen interactome, which can reveal new biology and uncover novel targets for the development of antivirals against highly pathogenic RNA viruses.
KW - arenaviruses
KW - host-directed antivirals
KW - host-virus interactions
KW - proximity proteomics
KW - viral replication
UR - http://www.scopus.com/inward/record.url?scp=85134491559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134491559&partnerID=8YFLogxK
U2 - 10.1073/pnas.2201208119
DO - 10.1073/pnas.2201208119
M3 - Article
C2 - 35858434
AN - SCOPUS:85134491559
SN - 0027-8424
VL - 119
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 30
M1 - e2201208119
ER -